A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer

LESSONS LEARNED: Monotherapy with prexasertib demonstrated modest activity in BRCA wild‐type, recurrent triple‐negative breast cancer, highlighting the unmet need for combination treatment strategies. Neutropenia, anemia, and thrombocytopenia are common with the use of prexasertib but are manageable...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Gatti‐Mays, Margaret E., Karzai, Fatima H., Soltani, Sanaz N., Zimmer, Alexandra, Green, Jeffrey E., Lee, Min‐Jung, Trepel, Jane B., Yuno, Akira, Lipkowitz, Stanley, Nair, Jayakumar, McCoy, Ann, Lee, Jung‐Min
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2020
Sujets:
Clinical Trial Results
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938394/
https://ncbi.nlm.nih.gov/pubmed/32510664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0491
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires